Sinovac Biotech (SVA) shareholder Heng Ren Partners, LLC funds sent an open letter to Sinovac’s shareholders outlining the numerous and decisive motion that Sinovac’s Board of Directors must take to create liquidity and release money to shareholders. Specifically, Heng Ren demands that Sinovac’s Board of Directors announce a distribution of $8.9B in money to its shareholders and cause the resumption of trading of the corporate’s shares. “After announcing a plan to distribute money to shareholders, the Company must take all motion mandatory to cause the resumption of trading of Sinovac’s shares on NASDAQ. The Board must immediately take and disclose all steps that it’s taking to make this occur. The Board must inform shareholders of a transparent timeline as to when the trading of Sinovac’s shares will resume on NASDAQ. The Board must prevent any trading, by Company management or otherwise, of Sinovac’s shares until full disclosure is product of the Company’s financial condition and other material information. Shareholders are entitled to all information mandatory to find out which additional actions, if any, are warranted.”

Published first on TheFly – the final word source for real-time, market-moving breaking financial news. Try Now>>

See the highest stocks beneficial by analysts >>

Read More on SVA:

Questions or Comments in regards to the article? Write to editor@tipranks.com